SCHEMBL5032539

SCHEMBL5032539

O=C(O)c1csc(N(C(=O)c2ccccc2Cl)c2ccc(OC(F)(F)F)cc2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.43
TDP1 Q9NUW8 1/20 0.41
GPBAR1 Q8TDU6 1/20 0.39
ALDH1A1 P00352 1/20 0.39
HTT P42858 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
LDHA P00338 1/20 0.38
AKR1C2 P52895 1/20 0.36
AKR1C1 Q04828 1/20 0.36
PTGER2 P43116 1/20 0.36
EIF4E P06730 1/20 0.36
TLR7 Q9NYK1 1/20 0.36
GCGR P47871 1/20 0.36
GIPR P48546 1/20 0.36
LIPE Q05469 2/20 0.35
DHODH Q02127 2/20 0.35
SCN10A Q9Y5Y9 1/20 0.35
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5035123 0.88 DHODH (0.42) KDM4ESMN1; SMN2LDHAAKR1C2AKR1C1
SCHEMBL5038957 0.87 LDHA (0.39) KDM4ERAB9ALDHAAKR1C2AKR1C1
SCHEMBL5035942 0.87 RAB9A (0.41) KDM4ETDP1GPBAR1ALDH1A1HTT
SCHEMBL5032520 0.87 LMNA (0.47) KDM4EALDH1A1HTTRAB9ASMN1; SMN2
SCHEMBL5032598 0.86 RAB9A (0.44) KDM4ETDP1ALDH1A1HTTRAB9A
SCHEMBL5034980 0.85 KDM4E (0.47) KDM4ETDP1ALDH1A1HTTRAB9A
SCHEMBL5034677 0.82 LIPE (0.43) KDM4ETDP1ALDH1A1HTTRAB9A
SCHEMBL5034675 0.82 LIPE (0.43) KDM4ETDP1ALDH1A1HTTRAB9A
SCHEMBL5032603 0.81 LIPE (0.41) KDM4EGPBAR1ALDH1A1HTTRAB9A
SCHEMBL5023491 0.79 KDM4E (0.42) KDM4ETDP1GPBAR1ALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7371751-B2 Thiazole derivatives HOFFMANN-LA ROCHE INC. (US) 2008-05-13 US disclosed
EP-1694673-B1 THIAZOLE DERIVATES HOFFMANN LA ROCHE (CH) 2008-01-16 EP disclosed
EP-1694673-A1 NOVEL THIAZOLE DERIVATES F.HOFFMANN-LA ROCHE AG (CH) 2006-08-30 EP disclosed
US-20050153962-A1 Thiazole derivatives HOFFMANN-LA ROCHE INC. 2005-07-14 US disclosed
WO-2005058887-A1 NOVEL THIAZOLE DERIVATES F. HOFFMANN-LA ROCHE AG (CH) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050153962-A1 Thiazole derivatives CNR1, CNR2, GPR119 KDM4E 3200/4885TDP1 3459/4885GPBAR1 49/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.